Fortrea (FTRE) Fireside Chat summary

Introduction and agenda

• Discussion focused on recent financial developments, operational progress post-spin, and future outlook.

Background and experience of the speaker

• Jill McConnell has a background in large pharma, with nearly two decades at GlaxoSmithKline in finance roles across drug development.

• She served as CFO of Labcorp's Drug Development business, leading finance transformation and ERP implementation.

• Transitioned to her current CFO role following the company’s spin, bringing sponsor-side perspective.

Current industry trends

• Industry-wide, mid-single-digit growth is expected for the year, with a rebound from prior biotech slowdowns.

• Oncology trials, which are a significant portfolio component, are experiencing slower patient recruitment.